Physician profile
Wesley E Moore
NPI 1053792069
$3,127.94
in general payments reported to CMS, 2019-2025
32 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $279 · 2021: $177 · 2022: $587 · 2023: $587 · 2024: $528 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $469.68 | 2021-2025 | |
| Lilly USA, LLC | $385.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $331.58 | 2020-2025 | |
| Novo Nordisk INC | $234.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $230.97 | 2022-2025 | Endurant Iis, Minimed 780g |
| Shield Therapeutics INC | $119.02 | 2022-2024 | Accrufer |
| Astrazeneca Pharmaceuticals Lp | $110.12 | 2021-2024 | Farxiga, Airsupra |
| Corcept Therapeutics | $102.95 | 2022-2023 | Korlym |
| Glaxosmithkline, LLC. | $99.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $98.62 | 2022-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $95.05 | 2019-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $94.91 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.35 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $81.68 | 2020-2025 | |
| Abbott Laboratories | $77.93 | 2022-2024 | Freestyle Libre |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $58.25 | 2025 | Auvelity |
| Allergan, INC. | $55.35 | 2020 | |
| Henry Schein, INC. | $48.68 | 2019 | |
| Merck Sharp & Dohme LLC | $46.62 | 2020-2022 | |
| Tolmar, INC. | $44.05 | 2025 | Jatenzo |
| Takeda Pharmaceuticals U.S.A., INC. | $39.66 | 2025 | Eohilia |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.16 | 2022 | |
| Exact Sciences Corporation | $34.20 | 2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $22.69 | 2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.19 | 2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $16.99 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $16.66 | 2025 | Austedo Xr |
| Insulet Corporation | $16.55 | 2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.12 | 2024 | |
| Almatica Pharma LLC | $14.12 | 2024 | Loreev Xr |
| Corium, LLC | $6.49 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.